Abstract: The present invention relates to compositions without added iron and methods for prophylactic nutritional supplementation and therapeutic nutritional supplementation. Specifically, the method involves administering to an individual a composition comprising carotenoids, vitamin E, vitamin D, vitamin C, thiamine, riboflavin, niacin, folic acid, pyridoxine, biotin, pantothenic acid, cobalamin, magnesium, manganese, zinc, selenium, chromium, copper, alpha lipoic acid, and lutein, wherein the composition is free of added iron.

Abstract: Methods and topical pharmaceutical formulations are provided for the treatment of nail fungus (onychomycosis). The invention involves a pharmacologically active antifungal agent, plus a pharmaceutically acceptable base in a formulation having a pH of 7.5 to about 13.0, preferably about 8.0 to 11.5, and most preferably about 8.5 to 10.5. These basic formulations permeate the nail and are effective in treating fungal infections of the nail and surrounding tissues.

Abstract: A treatment for brain, spinal and nerve injury comprising use of a substance P receptor antagonist optionally in combination with a magnesium compound. There is also provided a formulation for use in this treatment comprising a substance P receptor antagonist and a magnesium compound.

Abstract: The invention relates to methods and compositions for delivering iron to an iron-deficient patient, more particularly, to methods whereby an iron complex comprising divalent or trivalent ionic iron complexed with one or more low molecular weight anions is administered to a patient by transfer from dialysate. A complex selected according to the invention is non-polymeric; soluble in an aqueous medium; chemically stable, thereby preventing the dissociation of iron ions from the anions under conditions according to the invention; and can be well absorbed into blood and the living body. Also provided are dialysate compositions including therein an iron complex selected according to the invention, and dialysate concentrates which may be diluted to yield an inventive dialysate composition.

Abstract: A method of treating patients, particularly for pain and/or symptoms of erythromelalgia, and other neurovascular or neuropathic disorders, etc. involves administering high doses of magnesium. The magnesium is introduced through several daily administrations, totaling approximately 2-12 times the RDA for magnesium. These higher levels are achieved through increasing daily dosage amounts gradually in response to patient tolerance and until beneficial results are seen. Total magnesium intake is divided over several doses per day and taken with copious amounts of water.

Abstract: Improved area decontamination products and methods of use thereof are provided which include reactive nanoparticles (e.g., metal oxides, hydroxides and mixtures thereof) with one or more biocides and a liquid carrier for the nanoparticles and biocide(s). The products may be formulated for area decontamination as sprays, fogs, aerosols, pastes, gels, wipes or foams, and the presence of reactive nanoparticles enhances the neutralization of undesirable chemical or biological compounds or agents. The nanoparticles may be from the group consisting of the alkali metal, alkaline earth metal, transition metal, actinide and lanthanide oxides and hydroxides and mixtures thereof. In preferred forms, nanocrystalline oxides and hydroxides of Al, Ca, Ce, Mg, Sr, Sn, Ti and Zn are employed having single crystallite sizes of up to about 20 nm and surface areas of at least about 15 m2/g.

Abstract: A topical composition and method for the treatment of the symptoms of diaper rashes and skin irritations caused by acidic secretions comprising a) a pH-raising ingredient selected from the group consisting of sodium hydrogen carbonate (bicarbonate of soda), magnesium hydroxide, calcium carbonate, aluminum hydroxide, and mixtures thereof; b) an anhydrous base ointment; c) polysorbate 80; d) a pharmaceutically acceptable diluent; and e) butylated hydroxy toluene, wherein said pharmaceutically acceptable diluent is purified water. The pH of the topical composition is adjusted by adding droplets of glacial acetic acid. The composition can also further comprise AQUAPHOR™. Embodiments disclosed include a cream, dusting powder, spray, bath soak and effervescent tablet, and also the application of the lotion composition to a bodyside diaper liner.

Abstract: A method is provided to take advantage of naturally occurring factors that influence gender selection in such a way as to create a bias to conceive a specific gender. This is accomplished by teaching a woman how to recognize the various stages of her menstrual cycle and how and when to use ovulation predictor reagent strips to accurately predict when ovulation will occur. Specific instructions are provided as to when a couple should engage in intercourse. The method for influencing the chances of conceiving a child of a selected gender includes the steps of following a selected diet; supplementing said diet with selected nutriceuticals; douching with a selected douche prior to intercourse; and selectively timing intercourse.

Abstract: Treatment with magnesium produces a inhibition of acute stent thrombosis under high-shear flow conditions without any hemostatic or significant hemodynamic complications.

Abstract: This invention relates to a biocidal composition resistant to the formation of a gel and to the method for stabilizing a concentrate containing, in addition to the biocide, a carbodiimide, a lipophilic/hydrophilic emulsifier mixture having a HLB of 6 to 20 and optionally an oil and/or an alkoxylated ester of a polyhydroxylated compound, by adding to the concentrate an effective anti-gelling amount of an anti-gelling agent selected from the group of an inorganic oxide, a epoxidized naturally occurring or synthetic vegetable oil and an epoxylated ester of a saturated or unsaturated C6 to C18 aliphatic acid optionally containing hydroxy substitution and mixtures of the foregoing anti-gelling agents.

Abstract: Compositions and methods for treating wounds to significantly reduce the healing time, reduce the incidence of scar formation, improve the success of skin grafts, reduce the inflammatory response and providing anti-bacterial treatments to a patient in need thereof, that include small non-interlinked particles of bioactive glass or highly porous bioactive glass, are disclosed. Anti-bacterial solutions derived from bioactive glass, and methods of preparation and use thereof, are also disclosed. The compositions include non-interlinked particles of bioactive glass, alone or in combination with anti-bacterial agents and/or anti-inflammatory agents. The compositions can include an appropriate carrier for topical administration. Anti-bacterial properties can be imparted to implanted materials, such as prosthetic implants, sutures, stents, screws, plates, tubes, and the like, by incorporating small bioactive glass particles or porous bioactive glass into or onto the implanted materials.

Abstract: The pharmaceutical composition of the invention, which comprises a benzimidazole compound of the formula wherein R1 is hydrogen, alkyl, halogen, cyano, carboxy, carboalkoxy, carboalkoxyalkyl, carbamoyl, carbamoylalkyl, hydroxy, alkoxy, hydroxyalkyl, trifluoromethyl, acyl, carbamoyloxy, nitro, acyloxy, aryl, aryloxy, alkylthio or alkylsulfinyl, R2 is hydrogen, alkyl, acyl, carboalkoxy, carbamoyl, alkylcarbamoyl, dialkylcarbamoyl, alkylcarbonylmethyl, alkoxycarbonylmethyl or alkylsulfonyl, R3 and R5 are the same or different and each is hydrogen, alkyl, alkoxy or alkoxyalkoxy, R4 is hydrogen, alkyl, alkoxy which may optionally be fluorinated, or alkoxyalkoxy, and m is an integer of 0 through 4, and a basic inorganic salt stabilizing agent, is physically stable. Magnesium and calcium basic inorganic salt stabilizing agents are particularly useful.

Abstract: A biocide comosition useful for industrial materialsl comrising at least one metal oxide and at least one metal salt, wherein said at least one metal oxide is in a molar ratio of between 4:1 and 1:2 with said meal salt. The invention additionally relates to a process for roducing a biocide composition, comprising the steps of mixing a metal salt solution with at least one metal oxide in a molar ratio of between 4:1 and 1:2 oxide to salt and drying the resultant mixture thereby forming a cement powder.

Abstract: Treatment with magnesium produces a inhibition of acute stent thrombosis under high-shear flow conditions without any hemostatic or significant hemodynamic complications.

Abstract: A gel formulation is combined with a bactericidal concentrate which is a liquid mixture of about 1000 parts by volume of ultra pure water having an electrical resistance of 16-26 megohms, total dissolved solids of less than 0.04 parts per million and a specific conductance of less than 0.10 mho with about 1.2 to 3 parts by volume of Willard Water as prepared in accordance with U.S. Pat. No. 3,893,943. The bactericidal liquid concentrate in the amount of 3.5 to 12 ml in one liter of gel formulation is applied directly to a skin surface area having a burn or other dermal lesion to protect the area from bacterial contamination.

Abstract: A composition for controlling growth of pathological organisms on a plant, said composition comprises an effective amount of one or more of metal ion(s); one or more of chelating agent(s); and phosphorous acid, and/or salt or hydrate thereof, said composition is in an agriculturally compatible carrier or vehicle.

Abstract: An antacid and laxative tablet comprising magnesium oxide particles as an effective component, wherein

Abstract: Ectoparasites, such as fleas, ticks, mites and lice, are removed from a human or animal host after applying a composition that causes the temperature of the treated area to become higher or lower than normal. In one embodiment, treatment is effected by applying a composition that releases heat when contacted with water. The elevated or decreased temperature immobilizes the parasites and facilitates their mechanical removal, such as by combing.

Abstract: The invention relates to compositions and methods for treating and/or preventing lower gastrointestinal (GI) disorders in mammalian patients, more particularly for alleviating and/or preventing the lower GI symptoms associated with such disorders.

Abstract: The invention relates to compositions and methods for treating and/or preventing lower gastrointestinal (GI) disorders in mammalian patients, more particularly for alleviating and/or preventing the lower GI symptoms associated with such disorders.

Abstract: The present invention relates a hexane bioactive fraction and obtained from the roots of an aromatic plant named Vetiveria zizanioides commonly found in India for inhibiting the growth of drug resistant bacterial infections in humans and animals; also relates to a pharmaceutical composition comprising the bioactive extract with other additives for inhibiting the growth of drug resistant bacterial infections in humans and animals and a process for the isolation of said bioactive extract

Abstract: The present invention provides a periodontal composition compounded to include at least one alkaline agent to render a gel or paste having a pH of at least 9.0 to 11.0, and preferably 9.5 to 10.0. The preferred alkaline agent included in the composition is potassium hydroxide, and the composition preferably also includes aluminum hydroxide, calcium carbonate and magnesium carbonate. Of these agents, potassium hydroxide is the most basic compound utilized.

Abstract: Methods and pharmaceutical compositions for protecting pharmaceutical compounds (or drugs) in acidic environments are provided. Methods of treatment using formulations capable of protecting pharmaceutical compounds in acidic environments are also provided. Formulations provided generally comprise a therapeutically effective amount of at least one pharmaceutical compound, and a pharmaceutically acceptable protectant. The pharmaceutically acceptable protectant of the invention generally comprises a water-soluble acid neutralizer, and a water-insoluble acid neutralizer.

Abstract: A solid orally administrable pharmaceutical dosage form for the treatment of gastric disorders includes a first portion containing a therapeutically effective amount of a histamine H2-receptor antagonist, and a second portion immediately adjacent the first portion without an intervening barrier disposed between the first portion and the second portion, the second portion containing a therapeutically effective amount of an antacid. Physical separation of the active ingredients into two different portions without a separating barrier has been found sufficient to prevent degradation of the histamine H2-receptor antagonist due to contact with the antacid. The invention therefore provides stabilization of a histamine H2-receptor antagonist-antacid combination tablet which is comparable to known multiple portion tablets, but without an intervening barrier between the antacid portion and the histamine H2-receptor antagonist portion.

Abstract: A topical composition and method for the treatment of the symptoms of diaper rashes and skin irritations caused by acidic secretions comprising a) a pH-raising ingredient selected from the group consisting of sodium hydrogen carbonate (bicarbonate of soda), magnesium hydroxide, calcium carbonate, aluminum hydroxide, and mixtures thereof; b) an anhydrous base ointment; c) polysorbate 80; d) a pharmaceutically acceptable diluent; and e) butylated hydroxy toluene, wherein said pharmaceutically acceptable diluent is purified water. The pH of the topical composition is adjusted by adding droplets of glacial acetic acid. The composition can also further comprise AQUAPHOR™. Embodiments disclosed include a cream, dusting powder, spray, bath soak and effervescent tablet, and also the application of the lotion composition to a bodyside diaper liner.

Abstract: A method of treating solid neoplastic diseases is disclosed, which involves administering to a host in need of such treatment an effective amount of a pharmaceutically acceptable magnesium salt or complex, which can be a pharmaceutically acceptable inorganic magnesium salt such as magnesium pyrophosphate, or a pharmaceutically acceptable organic magnesium salt. The composition can be administered orally, parenterally, cutaneously or mucosally, and can be given, for example, in an amount of magnesium which is from 2 to 12 mg per kg of body weight daily. Preferred compositions include magnesium lactate, magnesium aspartate, magnesium acetate, and magnesium pyrophosphate. Neoplastic diseases amenable to the method include adenocarcinoma. The method can include administering with the magnesium salt or complex an effective amount of a pharmaceutically acceptable magnesium fixing substance, such as vitamin B6.

Abstract: Disclosed are far-infrared emission powders and resin-coated steel plates with antibacterial activity and far-infrared emission properties. In addition to being 0.9 or higher in emissivity, the far-infrared emission powders are inhibitory against the growth of bacteria, with a pH value of 7.5-10.5 in its saturate aqueous solution. A coating material comprising 5-100 parts by weight of the powder per 100 parts by weight of a resin is coated to a dry thickness of 5-60 &mgr;m on an electromagnetic shield steel plate without interruption of the intrinsic electromagnetic shield properties of the steel plate.

Abstract: A multinutrient nutritional supplement is provided that is designed to be most effective in optimizing health, increasing the immunity and decreasing the instances and severity of infection particularly among children.

Abstract: A method of treating patients, particularly for pain and/or symptoms of erythromelalgia, and other neurovascular or neuropathic disorders, etc. involves administering high doses of magnesium. The magnesium is introduced through several daily administrations, totaling approximately 2-12 times the RDA for magnesium. These higher levels are achieved through increasing daily dosage amounts gradually in response to patient tolerance and until beneficial results are seen. Total magnesium intake is divided over several doses per day and taken with copious amounts of water.

Abstract: A multinutrient nutritional supplement is provided that is designed to be most effective in optimizing health, increasing the immunity and decreasing the instances and severity of infection particularly among adolescents.

Abstract: This invention relates to a buffered phosphorus containing solution comprising at least one phosphorus compound selected from the group consisting of phosphorous acid, hypophosphorous acid, polyphosphorous acid polyhypophosphorous acid, and salts thereof. The solution also contains a buffer including an organic base in the form of a nitrogen containing compound and its conjugate acid. The solution may be used as a fertilizer or as a fungicide. The invention also relates to a method of preparing such a solution.

Abstract: A method for treating wood, characterized by impregnating wood with a metal-containing treating agent containing lignin and/or lignin derivatives and a metal, a metal compound, and/or a metal ion and oxidizing and/or macromolecularizing of the lignin and/or lignin derivatives in the wood to fix the metal component in the wood, and wood and woody materials obtained by the treating method. According to the method of the present invention, while effectively utilizing lignins, lignosulfonic acids, or lignosulfonic acid salts, leaching of the metal component can be suppressed to a low level to thereby retain the effects due to the incorporation of the metal components for a prolonged period.

Abstract: The invention relates to a mixture for use as wound dressing, which comprises: a) paraffins complying with DAB and/or synthetic waxes selected from the group consisting of montan waxes, petroleum waxes, Fischer-Tropsch waxes, polyolefin waxes, petrolatum, wax alcohols, and oxidates of the aforementioned substances; b) at least one metal hydroxide. The mixture is stable on prolonged storage at room temperature and promotes collagen regeneration in vivo in cases of bone trauma.

Abstract: A solution and the method of making the same for the treatment of osteoarthritis for treating symptoms of osteoarthritic conditions. The solution and the method of making the same for the treatment of osteoarthritis includes magnesium oxide; ethylenediaminetetraacetic acid; glycerin; and water, all of which are heated and added in a mixture which, after being cooled, is applied to the affected areas for treatment of the osteoarthritic condition.

Abstract: The pharmaceutical composition of the invention, which comprises a benzimidazole compound of the formula wherein R1 is hydrogen, alkyl, halogen, cyanot carboxy, carboalkoxy, carboalkoxyalkyl, carbamoyl, carbamoylalkyl, hydroxy, alkoxy, hydroxyalkyl, trifluoromethyl, acyl, carbamoyloxy, nitro, acyloxy, aryl, aryloxy, alkylthio or alkylsulfinyl, R2 is hydrogen, alkyl, acyl, carboalkoxy, carbamoyl, alkylcarbamoyl, dialkylcarbamoyl, alkylcarbonyl-methyl, alkoxycarbonylmethyl or alkylsulfonyl, R3 and R5 are the same or different and each is hydrogen, alkyl, alkoxy or alkoxyalkoxy, R4 is hydrogen, alkyl, alkoxy which may optionally be fluorinated, or alkoxyalkoxy, and m is an integer of 0 through 4, and a basic inorganic salt stabilizing agent, is physically stable. Magnesium and calcium basic inorganic salt stabilizing agents are particularly useful.

Abstract: A magnesium citrate oral solution comprising citric acid in an amount greater than 10% weight/volume; magnesium hydroxide in an amount ranging from about 1.5-5% weight/volume; and water. Most preferably, the citric acid is present in an amount of about 10.9% weight/volume. Another embodiment of the present invention is a method of treating constipation in a patient in need thereof. The method of this embodiment comprises administering an effective amount of an oral composition that comprises citric acid in an amount greater than 10% weight/volume. Preferably, the composition of this embodiment comprises citric acid in an amount of 10.9% weight/volume.

Abstract: Treatment with magnesium produces a inhibition of acute stent thrombosis under high-shear flow conditions without any hemostatic or significant hemodynamic complications.

Abstract: This invention relates, generally, to nutritional supplements which contain bioactive glass. These supplements are useful in both veterinary and human contexts. The compositions of the subject invention can be used to achieve a number of advantageous results including: enhancing the growth rates of young animals, osteogenic stimulation, strengthening the skeletal structure, and treating osteoporosis.

Abstract: Active bromine-containing solutions are produced and stabilized by reacting bromate and bromide salt solutions with an amino-complexing agent, such as sulfamic acid or sulfamate salt. The reaction is performed at a pH of less than 1 to create a complexed hypobromate. The pH of the active bromine-containing solution is raised to between 4 and 10 by adding an alkali to improve stability. Moreover, the solution is maintained below 30° C. during the alkali addition to retain bromine equivalent activity.

Abstract: A preparation which comprises calcium hydroxide, a dihydric or polyhydric alcohol and a fixed oil of vegetarian [sic] or animal origin and, where appropriate, pharmaceutically acceptable excipients; the production of a preparation of this type, the use of a preparation of this type for collagen regeneration and the use of a preparation of this type for producing a medicine for promoting collagen regeneration in vivo are described.

Abstract: The invention features methods for decreasing cell toxicity or death, and for decreasing polyglutamine aggregates and other amyloidogenic aggregates. The invention also features methods for treating a subject with a condition in which expanded polyglutamine repeats or amyloidogenic aggregates are present.

Abstract: The present invention describes a novel composition for the treatment of migraine, a common neurovascular syndrome, which can be elicited by functional and/or structural (symptomatic) disorders. This composition comprises taurine, coenzyme Q10 and additionally creatine, L-carnitine, certain vitamins and minerals, carbohydrates, proteins, fats and herbal extracts. Furthermore, the invention describes a method for the treatment of migraine.

Abstract: A dietary supplement for benefitting human bone health includes a calcium source, a source of vitamin D activity, and an osteoblast stimulant. A preferred calcium source is microcrystalline hydroxyapatite, which also contains protein (mostly collagen), phosphorus, fat, and other minerals. A preferred source of vitamin D activity is cholecalciferol, and a preferred osteoblast stimulant is ipriflavone. In addition to these basic ingredients, the composition can further include various other minerals known to occur in bone, vitamin C, and glucosamine sulfate, all of which exert beneficial effects on growth and maintenance of healthy bone. A method for benefitting human bone health involves administering a daily regimen of the dietary supplement.

Abstract: Disclosed is an evacuant possessing a sufficient evacuating effect in a small dose substantially without accompanying any irritation to bowel, irrespective of whether its preparations are in the form of tablets, liquids or elixirs, and having a suppressing action to odor of feces. This evacuant is characterized by containing an active magnesium oxide which has a BET value (surface area in terms of m2/g) of at least 21, preferably 21-50, more preferably 30-40 and is excellent in acid reactivity, and may preferably be incorporated with lactic acid bacteria, a mixture of sporolactobacteria and yeast extracts and/or oligosaccharides. The preparations are preferably in the form of liquids, granules, tablets and capsules.

Abstract: An inorganic antimicrobial composition has the formula AB2O4, wherein A and B are low temperature far infrared irradiating metals, A is Mg, Zn, Mn, Ni, Co, or Fe(II), B is Al, Cr(III), Mn(III) or Fe(III), and O is oxygen. An antimicrobial article is made by coating said composition on a porous honeycomb-shaped substrate. An organic antimicrobial article is made from a quaternary ammonium salt coated on a porous honeycomb-shaped substrate. Processes of making the antimicrobial articles are provided.

Abstract: Compositions comprising glutamine in combination with other nutrients, including N-acetyl-cysteine and Vitamins A, C, E are disclosed. Such compositions can be administered for promoting recovery in patients undergoing elective surgery and for treating multiple organ system failure.

Abstract: What is shown is an animal blood anticoagulant compound useful in the meat packing industry generally, and in slaughterhouse operations, particularly. The anticoagulant is effective when diluted with water at higher dilution ratios than earlier anticoagulants. In some field trials, this anticoagulant was at least as effective as previously known commercial anticoagulants when diluted by an additional 30%. The present anticoagulant preparation concentrate is an aqueous mixture of soft water (55.0%-65.0/%, w/w); tetrasodium ethylene diamine tetraacetate (Na4EDTA) (0.5%-3.0%, w/w); sodium hexametaphosphate (17.0%-24.0%, w/w); citric acid (5.0%-9.0%, w/w); and sodium hydroxide (4.0%-7.0%, w/w) to obtain a balanced pH that provides optimal chelating and anticoagulant activity. Optimal anticoagulant performance has been found to occur in the range of between pH 6.6 and pH 7.2.

Abstract: This invention relates to a method for treating inflammatory symptoms such as burning, redness, itching, swelling and pain which accompany skin disorders other than wounds of the skin. The method comprising topical application of a topical medicinal composition comprising a non-interlinked, particulate bioactive glass mixed with a topical medicinal carrier to the site of the skin disorder.

Abstract: The concentrate is a liquid mixture of about 1000 parts by volume of ultra pure water having an electrical resistance of 16-26 megohms, total dissolved solids of less than 0.04 parts per million and a specific conductance of less than 0.10 microhmo to about 1.2 to 3 parts by volume of Willard Water as prepared in accordance with U.S. Pat. No. 3,893,943. The liquid concentrate is applied directly to a skin surface area having a burn or other dermal lesion to protect the area from bacterial contamination.

Abstract: The pharmaceutical composition of the invention, which comprises a benzimidazole compound of the formula wherein R1 is hydrogen, alkyl, halogen, cyano, carboxy, carboalkoxy, carboalkoxyalkyl, carbamoyl, carbamoylalkyl, hydroxy, alkoxy, hydroxyalkyl, trifluoromethyl, acyl, carbamoyloxy, nitro, acyloxy, aryl, aryloxy, alkylthio or alkylsulfinyl, R2 is hydrogen, alkyl, acyl, carboalkoxy, carbamoyl, alkylcarbamoyl, dialkylcarbamoyl, alkylcarbonylmethyl, alkoxycarbonylmethyl or alkylsulfonyl, R3 and R5 are the same or different and each is hydrogen, alkyl, alkoxy or alkoxyalkoxy, R4 is hydrogen, alkyl, alkoxy which may optionally be fluorinated, or alkoxyalkoxy, and m is an integer of 0 through 4, and a basic inorganic salt stabilizing agent, is physically stable. Magnesium and calcium basic inorganic salt stabilizing agents are particularly useful.